Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action

Authors


: Dr Beáta Sperlágh, as above.
E-mail: sperlagh@koki.hu

Abstract

In this study we investigated the effect of cannabinoids on [3H]glutamate release from hippocampal synaptosomes of rat and CB1-null mutant mouse. In the rat, cannabinoid receptor agonists, i.e. CP55,940 (EC50, 0.84 μm), WIN55,212-2 (EC50, 3.47 μm), ACEA (EC50, 17.8 μm), and R-(+)-methanandamide (EC50, 19.8 μm) concentration-dependently inhibited the 25-mm-K+ depolarization-evoked release of [3H]glutamate and, among them, WIN55,212-2 displayed the greatest efficacy. The CB1 receptor antagonists SR141716A (1–5 μm) and AM251 (1 μm) and the VR1 vanilloid receptor antagonist capsazepine (10 μm) did not antagonize the effect of the agonists. SR141716A by itself attenuated the evoked [3H]glutamate release. WIN55,212-2 inhibited the release of [3H]glutamate in \mathrm{CB}^{\,-/-\,}_{1} mice as well. These data demonstrate that the action of cannabinoids on glutamate release in the hippocampus is pharmacologically distinct and independent from the cloned CB1 receptor.

Ancillary